Drug Approval | December 19, 2022
Sun Pharmaceutical receives warning letter from USFDA for Halol facility
The Halol facility was placed under Import Alert by USFDA.
The Halol facility was placed under Import Alert by USFDA.
The investment will enable the company to enter European markets as well as enhance margins in current markets
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
It offers quick relief in various types of Coughs, Colds and Sore Throat,
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
The company will reduce wastage substantially, increase productivity, enhance environmental consciousness, save energy, optimally use natural resources, and expand its market penetration
Subscribe To Our Newsletter & Stay Updated
